Pre-hospital Pulse Glucocorticoid Therapy in Patients with ST-segment Elevation Myocardial Infarction Transferred for Primary Percutaneous Coronary Intervention: a Randomized Controlled Trial (PULSE-MI)

Overview

Journal Trials

Publisher Biomed Central

Specialties General Medicine
Pharmacology

Date 2023 Dec 16

PMID 38102687

Authors

Jasmine Melissa Madsen

Laust Emil Roelsgaard Obling

Laura Rytoft

Fredrik Folke

Christian Hassager

Lars Bredevang Andersen

Niels Vejlstrup

Lia Evi Bang

Thomas Engstrom

Jacob Thomsen Lonborg

Affiliations

Soon will be listed here.

Abstract

Background: Inflammation in ST-segment elevation myocardial infarction (STEMI) is an important contributor to both acute myocardial ischemia and reperfusion injury after primary percutaneous coronary intervention (PCI). Methylprednisolone is a glucocorticoid with potent anti-inflammatory properties with an acute effect and is used as an effective and safe treatment of a wide range of acute diseases. The trial aims to investigate the cardioprotective effects of pulse-dose methylprednisolone administered in the pre-hospital setting in patients with STEMI transferred for primary PCI.

Methods: This trial is a randomized, blinded, placebo-controlled prospective clinical phase II trial. Inclusion will continue until 378 patients with STEMI have been evaluated for the primary endpoint. Patients will be randomized 1:1 to a bolus of 250 mg methylprednisolone intravenous or matching placebo over a period of 5 min in the pre-hospital setting. All patients with STEMI transferred for primary PCI at Rigshospitalet, Copenhagen University Hospital, Denmark, will be screened for eligibility. The main eligibility criteria are age ≥ 18 years, acute onset of chest pain with < 12 h duration, STEMI on electrocardiogram, no known allergy to glucocorticoids or no previous coronary artery bypass grafting, previous acute myocardial infarction in assumed culprit, or a history with previous maniac/psychotic episodes. Primary outcome is final infarct size measured by late gadolinium enhancement on cardiac magnetic resonance (CMR) 3 months after STEMI. Secondary outcomes comprise key CMR efficacy parameters, clinical endpoints at 3 months, the peak of cardiac biomarkers, and safety.

Discussion: We hypothesize that pulse-dose methylprednisolone administrated in the pre-hospital setting decreases inflammation and thus reduces final infarct size in patients with STEMI treated with primary PCI.

Trial Registration: EU-CT number: 2022-500762-10-00; Submitted May 5, 2022.

Clinicaltrials: gov Identifier: NCT05462730; Submitted July 7, 2022, first posted July 18, 2022.

References

Fearon W, Kobayashi Y . Invasive Assessment of the Coronary Microvasculature: The Index of Microcirculatory Resistance. Circ Cardiovasc Interv. 2017; 10(12). DOI: 10.1161/CIRCINTERVENTIONS.117.005361. View

Cain D, Cidlowski J . Immune regulation by glucocorticoids. Nat Rev Immunol. 2017; 17(4):233-247. PMC: 9761406. DOI: 10.1038/nri.2017.1. View

Nepper-Christensen L, Lonborg J, Ahtarovski K, Hofsten D, Kyhl K, Ghotbi A . Left Ventricular Hypertrophy Is Associated With Increased Infarct Size and Decreased Myocardial Salvage in Patients With ST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention. J Am Heart Assoc. 2017; 6(1). PMC: 5523642. DOI: 10.1161/JAHA.116.004823. View

Beijnink C, van der Hoeven N, Konijnenberg L, Kim R, Bekkers S, Kloner R . Cardiac MRI to Visualize Myocardial Damage after ST-Segment Elevation Myocardial Infarction: A Review of Its Histologic Validation. Radiology. 2021; 301(1):4-18. DOI: 10.1148/radiol.2021204265. View

Giugliano G, Giugliano R, Gibson C, Kuntz R . Meta-analysis of corticosteroid treatment in acute myocardial infarction. Am J Cardiol. 2003; 91(9):1055-9. DOI: 10.1016/s0002-9149(03)00148-6. View

Lonborg J, Vejlstrup N, Kelbaek H, Holmvang L, Jorgensen E, Helqvist S . Final infarct size measured by cardiovascular magnetic resonance in patients with ST elevation myocardial infarction predicts long-term clinical outcome: an observational study. Eur Heart J Cardiovasc Imaging. 2012; 14(4):387-95. DOI: 10.1093/ehjci/jes271. View

Lee S, Kim H, Youm J, Dizon L, Song I, Jeong S . Non-genomic effect of glucocorticoids on cardiovascular system. Pflugers Arch. 2012; 464(6):549-59. DOI: 10.1007/s00424-012-1155-2. View

Jenista E, Wendell D, Azevedo C, Klem I, Judd R, Kim R . Revisiting how we perform late gadolinium enhancement CMR: insights gleaned over 25 years of clinical practice. J Cardiovasc Magn Reson. 2023; 25(1):18. PMC: 10018965. DOI: 10.1186/s12968-023-00925-0. View

Goransson C, Ahtarovski K, Kyhl K, Lonborg J, Nepper-Christensen L, Bertelsen L . Assessment of the myocardial area at risk: comparing T2-weighted cardiovascular magnetic resonance imaging with contrast-enhanced cine (CE-SSFP) imaging-a DANAMI3 substudy. Eur Heart J Cardiovasc Imaging. 2018; 20(3):361-366. DOI: 10.1093/ehjci/jey106. View

10.

Liu B, Zhang T, Knight J, Goodwin J . The Glucocorticoid Receptor in Cardiovascular Health and Disease. Cells. 2019; 8(10). PMC: 6829609. DOI: 10.3390/cells8101227. View

11.

Caplan A, Fett N, Rosenbach M, Werth V, Micheletti R . Prevention and management of glucocorticoid-induced side effects: A comprehensive review: A review of glucocorticoid pharmacology and bone health. J Am Acad Dermatol. 2016; 76(1):1-9. DOI: 10.1016/j.jaad.2016.01.062. View

12.

Bondarenko O, Beek A, Hofman M, Kuhl H, Twisk J, van Dockum W . Standardizing the definition of hyperenhancement in the quantitative assessment of infarct size and myocardial viability using delayed contrast-enhanced CMR. J Cardiovasc Magn Reson. 2005; 7(2):481-5. DOI: 10.1081/jcmr-200053623. View

13.

Press R, Hiew F, Rajabally Y . Steroids for chronic inflammatory demyelinating polyradiculoneuropathy: evidence base and clinical practice. Acta Neurol Scand. 2015; 133(4):228-38. DOI: 10.1111/ane.12519. View

14.

Horby P, Lim W, Emberson J, Mafham M, Bell J, Linsell L . Dexamethasone in Hospitalized Patients with Covid-19. N Engl J Med. 2020; 384(8):693-704. PMC: 7383595. DOI: 10.1056/NEJMoa2021436. View

15.

Ong S, Hernandez-Resendiz S, Crespo-Avilan G, Mukhametshina R, Kwek X, Cabrera-Fuentes H . Inflammation following acute myocardial infarction: Multiple players, dynamic roles, and novel therapeutic opportunities. Pharmacol Ther. 2018; 186:73-87. PMC: 5981007. DOI: 10.1016/j.pharmthera.2018.01.001. View

16.

Doherty D, Sykes R, Mangion K, Berry C . Predictors of Microvascular Reperfusion After Myocardial Infarction. Curr Cardiol Rep. 2021; 23(3):21. PMC: 7902326. DOI: 10.1007/s11886-021-01442-1. View

17.

Lonborg J, Engstrom T, Ahtarovski K, Nepper-Christensen L, Helqvist S, Vejlstrup N . Myocardial Damage in Patients With Deferred Stenting After STEMI: A DANAMI-3-DEFER Substudy. J Am Coll Cardiol. 2017; 69(23):2794-2804. DOI: 10.1016/j.jacc.2017.03.601. View

18.

Ibanez B, James S, Agewall S, Antunes M, Bucciarelli-Ducci C, Bueno H . 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European.... Eur Heart J. 2017; 39(2):119-177. DOI: 10.1093/eurheartj/ehx393. View

19.

Keeley E, Boura J, Grines C . Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review of 23 randomised trials. Lancet. 2003; 361(9351):13-20. DOI: 10.1016/S0140-6736(03)12113-7. View

20.

Seropian I, Toldo S, Van Tassell B, Abbate A . Anti-inflammatory strategies for ventricular remodeling following ST-segment elevation acute myocardial infarction. J Am Coll Cardiol. 2014; 63(16):1593-603. DOI: 10.1016/j.jacc.2014.01.014. View